S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:ONCS

OncoSec Medical (ONCS) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.20
$0.94
52-Week Range
N/A
Volume
52.49 million shs
Average Volume
2.22 million shs
Market Capitalization
$1.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ONCS stock logo

About OncoSec Medical (NASDAQ:ONCS) Stock

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.


ONCS Stock News Headlines

ONCS - OncoSec Medical Incorporated
Why Is OncoSec Medical (ONCS) Stock Up 100% Today?
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
ONCS.OQ - | Stock Price & Latest News | Reuters
OncoSec Announces Pricing of $3.5 Million Public Offering
See More Headlines
Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Company Calendar

Last Earnings
12/14/2021
Today
10/04/2023
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCS
Employees
40
Year Founded
2011

Profitability

Net Income
$-34,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
4,494,000
Market Cap
$1.26 million
Optionable
Not Optionable
Beta
1.99

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Robert H. Arch
    President, CEO & Non-Independent Director
  • George Chi
    Chief Financial Officer
  • David Canton
    Vice President-Research & Development
  • Sandra Aung
    Chief Clinical Development Officer & Senior VP
  • Bridget O'Keeffe
    Vice President-Clinical Development













ONCS Stock - Frequently Asked Questions

Should I buy or sell OncoSec Medical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares.
View ONCS analyst ratings
or view top-rated stocks.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) announced its earnings results on Tuesday, December, 14th. The biotechnology company reported ($5.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.14) by $2.64.

When did OncoSec Medical's stock split?

OncoSec Medical's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How much money does OncoSec Medical make?

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $0.00. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($15.2865) on an earnings per share basis.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832.

This page (NASDAQ:ONCS) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -